The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment-Reference-Cited by-同舟云学术

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment

Published:2019-04-01 Issue:7 Volume:58 Page:943-947
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Suda Goki¹,Nakai Masato¹,Sho Takuya¹,Kimura Megumi¹,Shimazaki Tomoe¹,Maehara Osamu¹,Shigesawa Taku¹,Suzuki Kazuharu¹,Nakamura Akihisa¹,Ohara Masatsugu¹,Umemura Machiko¹,Kawagishi Naoki¹,Baba Masaru²,Natsuizaka Mitsuteru¹,Morikawa Kenichi¹,Ogawa Koji¹,Sakamoto Naoya¹,

Affiliation:

1. Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan

2. Department of Gastroenterology and Hepatology, Japan Community Health Care Organization (JCHO) Hokkaido Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/7/58_2077-18/_pdf

Reference24 articles.

1. 1. Iwasa Y, Otsubo S, Sugi O, et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol 12: 53-57, 2008.

2. 2. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 18: 1584-1593, 2007.

3. 3. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29: 257-263, 1999.

4. 4. Fabrizi F, Dixit V, Messa P, Martin P. Pegylated interferon mono-therapy of chronic hepatitis C in the dialysis population: systematic review and meta-analysis. Ther Apher Dial 19: 611-621, 2015.

5. 5. Suda G, Kudo M, Nagasaka A, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 14: 733-740, 2016.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized care approaches to hepatitis C therapy: recent advances and future directions;Expert Review of Anti-infective Therapy;2024-03-11

2. Changes in the estimated renal function after hepatitis C virus eradication with direct‐acting antiviral agents: Impact of changes in skeletal muscle mass;Journal of Viral Hepatitis;2021-02-24

3. Development of interferon-free, direct-acting antivirals treatment for Japanese patients with chronic hepatitis C infection and chronic kidney disease;Journal of Nippon Medical School;2021

4. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems;Journal of Gastroenterology and Hepatology;2020-07-28

5. High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C;Hepatology Research;2020-02-18